| Prognostic and Predictive Value of Blood Eosinophil Count, Fractional Exhaled Nitric Oxide, and Their Combination in Severe Asthma: A Post Hoc Analysis R Shrimanker, O Keene, G Hynes, S Wenzel, S Yancey, ID Pavord American Journal of Respiratory and Critical Care Medicine 200 (10), 1308-1312, 2019 | 104 | 2019 |
| Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised … ID Pavord, M Holliday, HK Reddel, I Braithwaite, S Ebmeier, RJ Hancox, ... The Lancet Respiratory Medicine 8 (7), 671-680, 2020 | 102 | 2020 |
| Synergistic activation of pro-inflammatory type-2 CD8+ T lymphocytes by lipid mediators in severe eosinophilic asthma B Hilvering, TSC Hinks, L Stöger, E Marchi, M Salimi, R Shrimanker, ... Mucosal immunology 11 (5), 1408-1419, 2018 | 63 | 2018 |
| Fractional exhaled nitric oxide nonsuppression identifies corticosteroid-resistant type 2 signaling in severe asthma S Couillard, R Shrimanker, R Chaudhuri, AH Mansur, LP McGarvey, ... American journal of respiratory and critical care medicine 204 (6), 731-734, 2021 | 52 | 2021 |
| The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study PJ McDowell, S Diver, F Yang, C Borg, J Busby, V Brown, R Shrimanker, ... The Lancet Respiratory Medicine 9 (10), 1174-1184, 2021 | 49 | 2021 |
| A new approach to the classification and management of airways diseases: identification of treatable traits R Shrimanker, XN Choo, ID Pavord Clinical Science 131 (10), 1027-1043, 2017 | 35 | 2017 |
| Interleukin-5 inhibitors for severe asthma: rationale and future outlook R Shrimanker, ID Pavord BioDrugs 31 (2), 93-103, 2017 | 26 | 2017 |
| Exacerbations of severe asthma in patients treated with mepolizumab R Shrimanker, ID Pavord, S Yancey, LG Heaney, RH Green, P Bradding, ... European Respiratory Journal 52 (6), 2018 | 19 | 2018 |
| Exacerbations of severe asthma in patients treated with mepolizumab R Shrimanker, ID Pavord, S Yancey, LG Heaney, RH Green, P Bradding, ... European Respiratory Journal 52 (6), 2018 | 19 | 2018 |
| Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker‐high and‐low severe asthma L Khalfaoui, FA Symon, S Couillard, B Hargadon, R Chaudhuri, S Bicknell, ... Allergy 77 (10), 2974-2986, 2022 | 16 | 2022 |
| Emerging biologics in severe asthma ID Pavord, B Hilvering, R Shrimanker Immunology and Allergy Clinics 36 (3), 609-623, 2016 | 13 | 2016 |
| Corticosteroid Responsiveness Following Mepolizumab in Severe Eosinophilic Asthma—A Randomized, Placebo-Controlled Crossover Trial (MAPLE) F Yang, J Busby, LG Heaney, ID Pavord, CE Brightling, K Borg, ... The Journal of Allergy and Clinical Immunology: In Practice 10 (11), 2925 …, 2022 | 9 | 2022 |
| Letting the right one in: evaluating the generalisability of clinical trials R Shrimanker, R Beasley, C Kearns European Respiratory Journal 52 (6), 2018 | 9 | 2018 |
| Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation S Diver, K Haldar, PJ McDowell, J Busby, V Mistry, C Micieli, V Brown, ... Allergy 77 (11), 3362-3376, 2022 | 8 | 2022 |
| Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing S Couillard, R Shrimanker, S Lemaire-Paquette, GM Hynes, C Borg, ... Thorax 77 (9), 933-938, 2022 | 8 | 2022 |
| Resistance to apoptosis underpins the corticosteroid insensitivity of group 2 innate lymphoid cells J Luo, Y Wu, R Shrimanker, S Go, Y Ye, C Hardman, J Nahler, YL Chen, ... Journal of Allergy and Clinical Immunology 144 (6), 1722-1726. e10, 2019 | 8 | 2019 |
| Resistance to apoptosis underpins the corticosteroid insensitivity of group 2 innate lymphoid cells J Luo, Y Wu, R Shrimanker, S Go, Y Ye, C Hardman, J Nahler, YL Chen, ... Journal of Allergy and Clinical Immunology 144 (6), 1722-1726. e10, 2019 | 8 | 2019 |
| Medical research council: refractory asthma stratification programme (RASP-UK consortium). The inflammatory profile of exacerbations in patients with severe refractory … PJ McDowell, S Diver, F Yang, C Borg, J Busby, V Brown, R Shrimanker, ... Lancet Respir Med 9 (10), 1174-1184, 2021 | 7 | 2021 |
| Late Breaking Abstract-Phenotyping Mepolizumab EXacerbations in severe eosinophilic asthma (MEX) PJ McDowell, S Diver, JF Yang, C Borg, J Busby, V Brown, R Shrimanker, ... European Respiratory Journal 56 (suppl 64), 2020 | 7 | 2020 |
| Late Breaking Abstract-Effect of timapiprant, a DP2 antagonist, on airway inflammation in severe eosinophilic asthma R Shrimanker, K Borg, C Connolly, S Thulborn, J Cane, L Xue, G Hynes, ... European Respiratory Journal 54 (suppl 63), 2019 | 7 | 2019 |
